Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
Emgality®▼ (galcanezumab) Device: Information on Air Bubbles
It is normal to have air bubbles in the pen or syringe. The medicine is injected under the skin (subcutaneous injection).
The presence of the air bubble is due to the syringe manufacturing process. It will not cause harm or affect the accuracy of the dose.1
Patients should not try to remove or expel the air bubble in the device. Removal of the air bubble before injecting is not necessary and not recommended.1
The instructions for using the pen or syringe included with the Package Leaflet, must be followed carefully. The pre-filled pen and pre-filled syringe is for total use only.2
After training, patients may self-inject galcanezumab if a healthcare professional determines that it is appropriate.3
3. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: February 13, 2019